[go: up one dir, main page]

MX2017009325A - Gel intestinal de levodopa y carbidopa y metodos de uso. - Google Patents

Gel intestinal de levodopa y carbidopa y metodos de uso.

Info

Publication number
MX2017009325A
MX2017009325A MX2017009325A MX2017009325A MX2017009325A MX 2017009325 A MX2017009325 A MX 2017009325A MX 2017009325 A MX2017009325 A MX 2017009325A MX 2017009325 A MX2017009325 A MX 2017009325A MX 2017009325 A MX2017009325 A MX 2017009325A
Authority
MX
Mexico
Prior art keywords
methods
levodopa
pharmaceutical composition
carbidopa
intestinal gel
Prior art date
Application number
MX2017009325A
Other languages
English (en)
Other versions
MX384262B (es
Inventor
Huang Ye
E Mackey Sean
Conjeevaram Rajkumar
Deac Alexandru
A Menges Randy
B Zimmerman Jayne
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2017009325A publication Critical patent/MX2017009325A/es
Publication of MX384262B publication Critical patent/MX384262B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La presente divulgación se refiere a (a) una composición farmacéutica mejorada que comprende un agente activo de levodopa y un agente activo de carbidopa, (b) métodos de producir la composición farmacéutica y (c) métodos de tratar la enfermedad de Parkinson y afecciones asociadas, que comprende administrar la composición farmacéutica a un sujeto con enfermedad de Parkinson.
MX2017009325A 2015-01-20 2016-01-20 Gel intestinal de levodopa y carbidopa y metodos de uso. MX384262B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105565P 2015-01-20 2015-01-20
US201562272922P 2015-12-30 2015-12-30
PCT/US2016/014005 WO2016118556A1 (en) 2015-01-20 2016-01-20 Levodopa and carbidopa intestinal gel and methods of use

Publications (2)

Publication Number Publication Date
MX2017009325A true MX2017009325A (es) 2018-02-09
MX384262B MX384262B (es) 2025-03-14

Family

ID=55410198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009325A MX384262B (es) 2015-01-20 2016-01-20 Gel intestinal de levodopa y carbidopa y metodos de uso.

Country Status (16)

Country Link
US (3) US10117843B2 (es)
EP (2) EP3247330A1 (es)
JP (4) JP2018503686A (es)
KR (1) KR20170103967A (es)
CN (2) CN116036064A (es)
AU (1) AU2016209420B2 (es)
BR (1) BR112017015613B1 (es)
CA (1) CA2974203A1 (es)
IL (1) IL253487A0 (es)
MA (1) MA41377A (es)
MX (1) MX384262B (es)
PH (1) PH12017501304A1 (es)
RU (1) RU2017129375A (es)
SG (1) SG11201705964YA (es)
TW (1) TW201639556A (es)
WO (1) WO2016118556A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6567049B2 (ja) 2014-10-21 2019-08-28 アッヴィ・インコーポレイテッド カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
WO2018017850A1 (en) * 2016-07-20 2018-01-25 Abbvie Inc. Levodopa and carbidopa intestinal gel and methods of use
CN113015531A (zh) 2018-11-15 2021-06-22 艾伯维公司 用于皮下施用的药物调配物
CN119510592A (zh) * 2023-08-22 2025-02-25 上海汉都医药科技有限公司 一种含有卡比多巴的药物中肼含量的检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
ATE118216T1 (de) 1989-04-20 1995-02-15 Zambon Spa Dopamin-medikament-vorstufe.
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
US20080051459A1 (en) * 2006-05-31 2008-02-28 Solvay Pharmaceuticals Gmbh Long term 24-hour intestinal administration of levodopa/carbidopa
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
US8193243B2 (en) 2009-05-19 2012-06-05 Neuroderm, Ltd. Continuous administration of dopa decarboxylase inhibitors and compositions for same
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
RU2740080C2 (ru) * 2010-11-15 2021-01-11 Нейродерм Лтд Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции
BR112013014304A2 (pt) 2010-12-10 2016-07-19 Synagile Corp composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
AU2012301770B8 (en) 2011-08-31 2017-01-19 Abbvie Inc. Sealing arrangement for syringe
RU2018144700A (ru) 2013-03-13 2019-02-18 Неуродерм Лтд Способ лечения болезни паркинсона
US20160278899A1 (en) * 2013-11-05 2016-09-29 Synagile Corporation Devices and methods for continuous drug delivery via the mouth
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Also Published As

Publication number Publication date
TW201639556A (zh) 2016-11-16
RU2017129375A (ru) 2019-02-21
MA41377A (fr) 2017-11-28
US20190142777A1 (en) 2019-05-16
JP2024129122A (ja) 2024-09-26
IL253487A0 (en) 2017-09-28
US20160206584A1 (en) 2016-07-21
MX384262B (es) 2025-03-14
CN116036064A (zh) 2023-05-02
EP3247330A1 (en) 2017-11-29
EP4470611A2 (en) 2024-12-04
SG11201705964YA (en) 2017-08-30
PH12017501304A1 (en) 2018-02-05
KR20170103967A (ko) 2017-09-13
US10117843B2 (en) 2018-11-06
JP2018503686A (ja) 2018-02-08
CN107427463A (zh) 2017-12-01
JP2023058678A (ja) 2023-04-25
JP2021073186A (ja) 2021-05-13
BR112017015613A2 (en) 2018-03-13
RU2017129375A3 (es) 2019-08-05
US20210046029A1 (en) 2021-02-18
EP4470611A3 (en) 2025-02-19
AU2016209420B2 (en) 2021-05-20
AU2016209420A1 (en) 2017-08-03
BR112017015613B1 (pt) 2023-11-28
WO2016118556A1 (en) 2016-07-28
CA2974203A1 (en) 2016-07-28
JP7232235B2 (ja) 2023-03-02

Similar Documents

Publication Publication Date Title
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
MX2017009325A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
WO2017184871A9 (en) Carbidopa and l-dopa prodrugs and methods of use
PH12018501072A1 (en) Modified release orally administered amino acid formulations
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2018008078A (es) Tecnologia de sinergismo anticuerpo-farmaco para el tratamiento de enfermedades.
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
EP3590338A3 (en) Medical treatments based on anamorelin
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
MX2022001772A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
EP4537846A3 (en) Anavex2-73 for the treatment of alzheimer s disease
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
HK1245638A1 (en) Levodopa and carbidopa intestinal gel and methods of use
AR103448A1 (es) Gel intestinal de levodopa y carbidopa y métodos de uso
AR130700A2 (es) Composiciones de grapiprant y métodos para su utilización
UA106471U (uk) Засіб для лікування дерматологічних захворювань
UA112489C2 (uk) Спосіб лікування вугрової хвороби шкіри обличчя та спини за індріксоном